Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how anticancer biosimilars have played a role in oncology in 2019.
Transcript
I would say, right now, the oncology biosimilars in the therapeutic space is still new and limited. It's only been a few months since we've had the first 2 become available in the market that's not in supportive care.
Thus far, it's been, from at least a health system perspective, it's been a slower uptake and utilization. But part of that is because there is the awareness and increasing awareness from stakeholders about when additional products are going to be coming to market.
So for these oncology disease-modifying agents, there's an awareness that there's going to be additional ones coming out in the next few months. So instead of making a decision at the point in time when the first ones are launched, if you know there's going to be more coming out in the near future, a lot of health systems are waiting to see, okay, well, let's make that decision at that time to see what's going to be the most viable and financially positive for us to utilize.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.